x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Society of Hematologic Oncology Insider news

Seriously simple podcasting

SOHO Insider delivers on the latest news in hematologic oncology and updates from the Society of Hematologic Oncology

science life sciences

All Episodes

12:19

Drs. O’Brien, Jain discuss FLAIR trial, BTK degraders...

Society of Hematologic Oncology Insider news ·

2025/10/30

In this episode of the SOHO Insider podcast, Susan O’Brien, MD, a professor of medicine from the Chao Family Comprehensive Cancer Center at the University of California, Irvine Medical Center, and Nitin Jain, MD, professor of medicine in the Department of Leukemia at the University of Texas MD Anderson Cancer Center, discuss updated results from the phase 3 FLAIR trial; the pair also speak about Bruton’s tyrosine kinase degraders in treating CLL.

en-US

1:40

Sagar Lonial, MD, on what to expect at SOHO...

Society of Hematologic Oncology Insider news ·

2025/10/17

Sagar Lonial, MD, and Saad Usmani, MD, provide a sneak peek on what attendees can expect to learn at SOHO Breakthroughs in Blood Cancers (SBBC). Dr. Lonial will be the presenter of the myeloma session at the meeting. His talk is scheduled for 1:35 pm Central time on November 20, 2025.SBBC is a new virtual meeting from SOHO and is chaired by Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center. SBBC takes place at 8 am—5 pm Central time on November 20, 2025. Register today at

en-US

8:56

Dr. Eytan Stein joins Dr. Saad Usmani on SOHO Insider...

Society of Hematologic Oncology Insider news ·

2025/10/10

Saad Usmani, MD, chief of the myeloma service and Eytan Stein, MD, chief of the leukemia service, both from Memorial Sloan Kettering Cancer Center, discuss menin inhibitors and the future of leukemia research in this podcast episode of SOHO Insider. Dr. Stein discusses the development of the first menin inhibitor approved the US Food and Drug Administration for relapsed or refractory acute leukemia with a KMTA translocation. “The response rate is in the range of 60% to 70%,” noted Dr. Stein,

en-US

8:09

Drs. Melody, Phillips talk glofitamab in MCL

Society of Hematologic Oncology Insider news ·

2025/09/23

In this podcast episode recorded at the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Megan Melody, MD, from Tampa General Hospital, spoke with Tycel J. Phillips, MD, from the City of Hope Cancer Center, on the latest advancements in mantle cell lymphoma (MCL), including the phase 1/2 trial in relapsed or refractory MCL recently published in the Journal of Clinical Oncology.In the trial led by Dr. Phillips, the investigators evaluated glofitamab monotherapy in

en-US

16:10

Drs. Kuykendall and Gerds discuss myelofibrosis...

Society of Hematologic Oncology Insider news ·

2025/08/27

SOHO Insider myeloproliferative neoplasms podcast host Andrew Kuykendall, MD, associate member in the Department of Malignant Hematology at the Moffitt Cancer Center, and guest Aaron Gerds, MD, MS, an associate professor at the Cleveland Clinic, discuss anemia in myelofibrosis in a SOHO Insider podcast.“I put anemia near the top of the list, or at least an equal footing with spleen and symptoms,” Dr. Gerds said. He also noted that 40% of myelofibrosis patients face anemia at diagnosis, with

en-US

10:55

SOHO Insider leukemia podcast with Drs. O’Brien and...

Society of Hematologic Oncology Insider news ·

2025/08/19

Listen to Susan O’Brien, MD, professor of medicine, and Catherine C. Coombs, MD, associate professor of medicine, both of the Chao Family Comprehensive Cancer Center at the University of California, Irvine, on the SOHO Insider podcast.They discuss frontline chronic lymphocytic leukemia (CLL) treatments from the EHA 2025 meeting in Milan along with the AMPLIIFY trial, presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in December 2024. The GAIA/CLL13 trial showed

en-US

13:36

Dr. Melody interviews Dr. Prica on Burkitt’s lymphoma...

Society of Hematologic Oncology Insider news ·

2025/08/06

SOHO Insider lymphoma podcast host Megan Melody, MD, an assistant professor at the University of South Florida and lymphoma and chimeric antigen receptor T-cell therapy specialist at Tampa General Hospital Cancer Institute interviews Anca Prica, MD, of Princess Margaret Cancer Centre, in this podcast episode.The pair discuss Dr. Prica’s paper on glofitamab and polatuzumab for refractory Burkitt’s lymphoma, which was published in The New England Journal of Medicine earlier in 2025.

en-US

8:47

SOHO President Phillip Scheinberg talks with Saad...

Society of Hematologic Oncology Insider news ·

2025/07/23

Saad Usmani, MD, chief of the myeloma service at Memorial Sloan Kettering Cancer Center, and Phillip Scheinberg, MD, president of the Society of Hematologic Oncology (SOHO), chat about SOHO’s vision, Annual Meeting, satellite meetings, and membership.To register for SOHO 2025, visit soho.click/2025. Become a SOHO member for free today. Listen to other SOHO Insider podcasts.

en-US

9:08

The journey of belantamab mafodotin in multiple myeloma

Society of Hematologic Oncology Insider news ·

2025/07/07

Host Saad Usmani, MD, chief of the myeloma service at Memorial Sloan Kettering Cancer Center in New York City, and Sagar Lonial, MD, FACP, professor and chair of the Department of Hematology and Medical Oncology at Winship Cancer Institute at Emory University, explore the journey of the antibody-drug conjugate (ADC) belantamab mafodotin, the first B-cell maturation antigen (BCMA)-targeted ADC approved by the US Food and Drug Administration (FDA) for patients with relapsed or refractory myeloma.Dr

en-US

12:07

Inside AML challenges with Drs. Jabbour, Daver

Society of Hematologic Oncology Insider news ·

2025/06/26

Elias Jabbour, MD, and Naval Daver, MD, both of the University of Texas MD Anderson Cancer Center, discuss challenges in TP53-mutated acute myeloid leukemia (AML) in this SOHO Insider podcast episode. Despite advances in other molecular subsets, TP53 AML has seen little meaningful progress in more than two decades. It remains a particularly aggressive form, especially common in older adults and therapy-related cases. Not all TP53 mutations are the same; prognosis worsens with high allelic burden,

en-US

18:44

Drs. Kuykendall and Hobbs on MPN care in 2025

Society of Hematologic Oncology Insider news ·

2025/06/02

Andrew Kuykendall, MD, of Moffitt Cancer Center in Tampa, Florida hosts a podcast on the latest news in myeloproliferative neoplasms (MPNs) with guest Gabriela Hobbs, MD, of Massachusetts General Research Institute. The pair discuss treatment goals for patients with MPNs, especially as treatments evolve and become more targeted. “As therapies get better, we can offer more to our patients,” Dr. Hobbs said. One upcoming abstract of interest at ASCO® 2025 included Dr. Kuykendall’s oral abstract,

en-US

16:11

Gwen Nichols speaks with Saad Usmani on CAR-T therapy...

Society of Hematologic Oncology Insider news ·

2025/05/14

Saad Usmani, MD, of Memorial Sloan Kettering Cancer Center in New York, and Gwen Nichols, MD, CMO of the Leukemia & Lymphoma Society discuss recent chimeric antigen receptor (CAR)-T cell therapy advancements and the current state of blood cancer research. Recent trials have shown cures in pediatric acute lymphoblastic leukemia. In myeloma, there has been an “amazing number of advances” by integrating multiple therapies, Dr. Nichols said. The impact of CAR-T is broadening, paving the way for

en-US

12:53

For CML, the science is here now access must follow

Society of Hematologic Oncology Insider news ·

2025/05/01

Jerald Radich, MD, of Fred Hutchinson Cancer Center in Seattle, sits down with Saad Usmani, MD, of Memorial Sloan Kettering Cancer Center in New York, to reflect on progress made in chronic myeloid leukemia (CML) and the work still ahead to ensure equitable care worldwide. “The issue with CML is that most of the CML in the world is in developing countries, and they can’t afford a drug, they can’t afford testing,” Dr. Radich said on the podcast. The pair also discussed current funding cuts. “As a

en-US

12:53

For CML, the science is here now access must follow

Society of Hematologic Oncology Insider news ·

2025/04/29

Jerald Radich, MD, of Fred Hutchinson Cancer Center in Seattle, sits down with Saad Usmani, MD, of Memorial Sloan Kettering Cancer Center in New York, to reflect on progress made in chronic myeloid leukemia (CML) and the work still ahead to ensure equitable care worldwide. “The issue with CML is that most of the CML in the world is in developing countries, and they can’t afford a drug, they can’t afford testing,” Dr. Radich said on the podcast. The pair also discussed

en-US

14 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter